Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 3/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 2/20 | 0.31 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18415105 | 0.95 | CNR2 (0.32) | CNR2KDM4EMAPTHPGDHTT | |
| SCHEMBL19425845 | 0.95 | KDM4E (0.33) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL21719130 | 0.90 | KDM4E (0.31) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL23502540 | 0.89 | CNR2 (0.34) | CNR2KDM4ECNR1KCNH2 | |
| SCHEMBL23502537 | 0.89 | CNR2 (0.34) | CNR2KDM4ECNR1KCNH2 | |
| SCHEMBL25825965 | 0.88 | KDM4E (0.31) | KDM4EMAPTHPGDHTTHSD17B10 | |
| SCHEMBL18516933 | 0.85 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL19934960 | 0.85 | CNR2 (0.40) | CNR2CNR1 | |
| SCHEMBL19646395 | 0.83 | GABRP (0.35) | CNR2KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL22858660 | 0.83 | GABRP (0.35) | CNR2KDM4EMAPTHPGDHSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | RELIVE THERAPEUTICS INC. (CA) | 2023-07-13 | — | — | US | disclosed |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AMGEN INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | Epizyme, Inc. | 2020-11-19 | — | — | US | disclosed |
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AMGEN INC. (US) | 2019-09-19 | — | — | US | disclosed |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | INFINITY PHARMACEUTICALS, INC. (US) | 2019-06-25 | — | — | US | disclosed |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | TWELVE THERAPEUTICS, INC. | 2018-02-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190284173-A1 | TRIAZOLE PHENYL COMPOUNDS AS AGONISTS OF THE APJ RECEPTOR | AGTR1, AGTR2, TBXA2R | CNR2 272/4885KDM4E 4276/4885MAPT 3966/4885 |
| US-10906890-B2 | Triazole phenyl compounds as agonists of the APJ receptor | AGTR1, AGTR2, TBXA2R | CNR2 272/4885KDM4E 4276/4885MAPT 3966/4885 |
| US-10329299-B2 | Heterocyclic compounds and uses thereof | PIK3CA, AKT1, AKT2 | CNR2 1102/4885KDM4E 4191/4885MAPT 2890/4885 |
| US-20230219942-A1 | COMPOUNDS COMPRISING A THREE RING CORE AS PD-1/PD-L1 BLOCKERS | CD274, PDCD1, PDCD1LG2 | CNR2 3710/4885KDM4E 1531/4885MAPT 1976/4885 |
| US-20200361914-A1 | SUBSTITUTED BENZENE AND 6,5-FUSED BICYCLIC HETEROARYL COMPOUNDS | BCOR, CYP2B6, AHR | CNR2 110/4885KDM4E 860/4885MAPT 4625/4885 |
| US-20180044346-A1 | HETEROCYCLIC COMPOUNDS AND USES THEREOF | PIK3CA, PIK3CD, PIK3CB | CNR2 1055/4885KDM4E 3893/4885MAPT 1605/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.